Novo Nordisk A/S (NYSE:NVO) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC trimmed its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 44.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 496,088 shares of the company's stock after selling 396,339 shares during the quarter. Janus Henderson Group PLC's holdings in Novo Nordisk A/S were worth $42,673,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Center for Financial Planning Inc. raised its holdings in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after acquiring an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL grew its stake in shares of Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after buying an additional 300 shares during the period. Transce3nd LLC purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $33,000. Kelly Lawrence W & Associates Inc. CA purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $39,000. Finally, Albion Financial Group UT boosted its position in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after purchasing an additional 278 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

NVO stock traded down $1.81 during trading on Friday, reaching $64.35. 18,941,653 shares of the company were exchanged, compared to its average volume of 6,547,867. The company has a market cap of $288.75 billion, a P/E ratio of 19.56, a PEG ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The stock's 50 day moving average price is $67.59 and its 200 day moving average price is $84.91. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NVO has been the subject of a number of research analyst reports. StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. BMO Capital Markets restated a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.